Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

1. Preoperative cell-free DNA concentration in plasma as a diagnostic and prognostic biomarker of clear cell renal cell carcinoma.Contemporary oncology (Poznan, Poland) · 2023
   Article
2. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation.BJU international · 2022
   Article
3. Decision-making in active surveillance in kidney cancer: current trends and future urine and tissue markers.World journal of urology · 2021
   Review
4. Atypical Response Patterns in Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors-Navigating the Radiologic Potpourri.Cancers · 2021
   Article
5. MCPIP1 contributes to clear cell renal cell carcinomas development.Angiogenesis · 2017
   Article
6. Paradigm shift in bacteriophage-mediated delivery of anticancer drugs: from targeted 'magic bullets' to self-navigated 'magic missiles'.Expert opinion on drug delivery · 2017
   Review
7. Overview of Transgenic Glioblastoma and Oligoastrocytoma CNS Models and Their Utility in Drug Discovery.Current protocols in pharmacology · 2016
   Review
8. Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study.Targeted oncology · 2015
   Article
9. MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC).Oncotarget · 2015
   Article
10. BRAFV600E immunopositive melanomas show low frequency of heterogeneity and association with epithelioid tumor cells: a STROBE-compliant article.Medicine · 2014
    Article
11. The Succinated Proteome of FH-Mutant Tumours.Metabolites · 2014
    Article
12. Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential.Urologic oncology · 2014
    Article
13. A role for cytosolic fumarate hydratase in urea cycle metabolism and renal neoplasia.Cell reports · 2013
    Article
14. The use of reverse phase protein arrays (RPPA) to explore protein expression variation within individual renal cell cancers.Journal of visualized experiments : JoVE · 2013
    Article
15. [Renal cancer biomarkers. What is justified?].Der Pathologe · 2012
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.